Biopure Appoints New Independent Auditor

CAMBRIDGE, Mass., April 10 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced today that it has engaged Vitale, Caturano & Company, Ltd as its independent auditor.

The audit committee of Biopure's board of directors made its selection after a review of audit firms that had expertise with public clients of Biopure's size and requirements.

Based in Boston, Massachusetts, Vitale, Caturano & Company, Ltd. is a large, regional registered public accounting firm. Vitale, Caturano & Company replaces Ernst & Young, LLP.

Biopure Corporation

Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer - 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer - 200 (bovine)], or HBOC-301, the only oxygen therapeutic approved for marketing by both the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Biopure has sold approximately 200,000 units of Oxyglobin since 1998.

SOURCE Biopure Corporation

Suggested Articles

The profit margins and management of Community Health Group raise questions about oversight of managed care insurers.

Financial experts are warning practices about the pitfalls of promoting medical credit cards to their patients.

A proposed rule issued by HHS on Tuesday would expand short-term coverage, a move Seema Verma said will have "virtually no impact" on ACA premiums.